Baseline patient characteristics
| . | Total, N = 35 . |
|---|---|
| Median age, y (range) | 64.0 (44.0-82.0) |
| Male sex (%) | 19 (54) |
| Eastern Cooperative Oncology Group Performance Score (%) | |
| 0 | 10 (29) |
| 1 | 14 (40) |
| 2 | 11 (31) |
| Organs involved (%) | |
| 0-1 | 16 (46) |
| 2 | 9 (26) |
| ≥ 3 | 10 (28) |
| Dominant site at diagnosis (%) | |
| Heart | 10 (28) |
| Peripheral nerve | 1 (3) |
| Skin | 3 (9) |
| Kidney | 17 (49) |
| Liver | 4 (11) |
| Previous treatment | 11 (31) |
| Previous regimens | |
| Thalidomide | 1 |
| Melphalan/dexamethasone | 4 |
| Dexamethasone | 3 |
| Melphalan | 6 |
| Prior autologous blood stem cell transplantation (%) | 7 (20) |
| Median laboratory characteristics (range) | |
| Creatinine, mg/dL | 1.2 (0.5-2.8) |
| Cardiac troponin T, ng/mL | 0.02 (0.1-0.22) |
| NT-proBNP, pg/mL | 1349.0 (0.0-25 926.0) |
| Disease stage, troponin/NT-ProBNP staging, (%) | |
| Stage 1 | 8 (23) |
| Stage 2 | 12 (34) |
| Stage 3 | 15 (43) |
| . | Total, N = 35 . |
|---|---|
| Median age, y (range) | 64.0 (44.0-82.0) |
| Male sex (%) | 19 (54) |
| Eastern Cooperative Oncology Group Performance Score (%) | |
| 0 | 10 (29) |
| 1 | 14 (40) |
| 2 | 11 (31) |
| Organs involved (%) | |
| 0-1 | 16 (46) |
| 2 | 9 (26) |
| ≥ 3 | 10 (28) |
| Dominant site at diagnosis (%) | |
| Heart | 10 (28) |
| Peripheral nerve | 1 (3) |
| Skin | 3 (9) |
| Kidney | 17 (49) |
| Liver | 4 (11) |
| Previous treatment | 11 (31) |
| Previous regimens | |
| Thalidomide | 1 |
| Melphalan/dexamethasone | 4 |
| Dexamethasone | 3 |
| Melphalan | 6 |
| Prior autologous blood stem cell transplantation (%) | 7 (20) |
| Median laboratory characteristics (range) | |
| Creatinine, mg/dL | 1.2 (0.5-2.8) |
| Cardiac troponin T, ng/mL | 0.02 (0.1-0.22) |
| NT-proBNP, pg/mL | 1349.0 (0.0-25 926.0) |
| Disease stage, troponin/NT-ProBNP staging, (%) | |
| Stage 1 | 8 (23) |
| Stage 2 | 12 (34) |
| Stage 3 | 15 (43) |